RVMD (STOCKS)
Revolution Medicines, Inc. Common Stock
$98.307100
+0.317100 (+0.32%)
Prev close: $97.990000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- CEO
- Mark A. Goldsmith
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $18,808.10M
- Employees
- 809
- P/E (TTM)
- -18.91
- P/B (TTM)
- 11.64
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
15
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-1.61 | $-1.45 | -0.1627 | -11.24% |
|
Jun 2025 (Q2)
|
$-1.31 | $-1.16 | -0.1486 | -12.79% |
|
Mar 2025 (Q1)
|
$-1.13 | $-1.11 | -0.0172 | -1.55% |
|
Dec 2024 (Q4)
|
$-1.12 | $-1.01 | -0.1133 | -11.25% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $75.32M |
| Operating Expenses | $1.04B |
| Research and Development | $880.49M |
| Other Operating Expenses | $156.57M |
| Operating Income/Loss | -$1.04B |
| Income/Loss From Continuing Operations After Tax | -$960.98M |
| Income/Loss From Continuing Operations Before Tax | -$961.73M |
| Net Income/Loss | -$960.98M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$960.98M |
| Net Income/Loss Available To Common Stockholders, Basic | -$960.98M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.19 |
| Diluted Earnings Per Share | -$5.19 |
| Basic Average Shares | 190,818,899 |
| Diluted Average Shares | 190,818,899 |
| Assets | $2.25B |
| Current Assets | $1.98B |
| Noncurrent Assets | $274.43M |
| Fixed Assets | $32.93M |
| Intangible Assets | $55.87M |
| Other Non-current Assets | $185.64M |
| Liabilities | $655.02M |
| Current Liabilities | $245.62M |
| Accounts Payable | $74.85M |
| Other Current Liabilities | $170.77M |
| Noncurrent Liabilities | $409.39M |
| Equity | $1.60B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.60B |
| Liabilities And Equity | $2.25B |
| Net Cash Flow From Operating Activities | -$761.79M |
| Net Cash Flow From Operating Activities, Continuing | -$761.79M |
| Net Cash Flow From Investing Activities | -$349.73M |
| Net Cash Flow From Investing Activities, Continuing | -$349.73M |
| Net Cash Flow From Financing Activities | $1.13B |
| Net Cash Flow From Financing Activities, Continuing | $1.13B |
| Net Cash Flow | $18.15M |
| Net Cash Flow, Continuing | $18.15M |
| Comprehensive Income/Loss | -$961.67M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$961.67M |
| Other Comprehensive Income/Loss | -$696.00K |